Section Review—Cardiovascular & Renal: Integrins and Cardiovascular Disease

References

• TRIP MD, CAS VM, VANCAPELLE FJC, VREEKEN J: Platelet hyperactivity and prognosis in survivors of myocardial Infarction. New Engl. J. Med. (1990) 322:1459–1454.
   PubMedGoogle Scholar
• HENDERSON MG, GOLDMAN S, COPELAND JG, MORITZ TE, HARKER LA: Antiplatelet or anticoagulant therapy after coronary bypass surgery: a meta analysis of clini-cal trials. Ann. Intern. Med. (1989) 111:743–750.
   PubMed Web of Science ®Google Scholar
• STEIN B, FUSTER V, ISRAEL DM, COHEN M, BADIMON L,BADIMON J, CHESEBRO J: Platelet inhibitor agents in cardiovascular disease: an update. J. Am. Coll. Cardiol. (1989) 14(4):813–836.
   PubMed Web of Science ®Google Scholar
• RISC GROUP: Risk of myocardial infarction and deathduring treatment with low dose aspirin and intrave-nous heparin in men with unstable coronary artery disease. Lancet (1990) 336:827–830.
   PubMed Web of Science ®Google Scholar
• COLLER B: Platelets and thrombolytic therapy. New Engl.J. Med. (1990) 322:33–42.
   PubMed Web of Science ®Google Scholar
• SIESS W: Molecular mechanisms of platelet activation. Physiological Rev. (1989) 69:58–178.
   PubMed Web of Science ®Google Scholar
• PATRONO C: Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. TIPS (1989) 10:453–458.
   PubMed Web of Science ®Google Scholar
• WHITI1E BJR, MONCADA S, VANE TR: Comparison of theeffects of prostacyclin (PGI2), prostaglandin Ei and D2 on platelet aggregation in different species. Prostagland-ins (1978) 16:373–388.
   PubMedGoogle Scholar
• TOPOL EJ, ELLIS SG, CALIFF RM, GEORGE BS, STUMP DC,BATES ER, NABEL EG, WALTON JA, CANDELA RJ, LEE KL, KLINE EM, PITT B, TAMI 4 GROUP: Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J. Am. Coll. Cardiol. (1989) 14(4):877–884.
   PubMed Web of Science ®Google Scholar
• MARGUERIE GA, PLOW EF, EDINGTON TS: Human plate-lets possess an inducible and saturable receptor specific for fibrinogen. J. Biol. Chem. (1979) 254(12):5357–5363. Identification of the fibrinogen receptor on platelets.
   Google Scholar
• PHILLIPS DR, CHARO IF, PARSIE LV, FITZGERALD LA: The •platelet membrane glycoprotein lIb-ma complex. Blood(1988) 71:831-843. A good review on the structure of GPIlb/Illa.
   Google Scholar
• PIERSCHBACHER MD, RUOSLAHTI E: Cell attachment activity of fibronectin can be duplicated by small syn-thetic fragments of the molecule. Nature (1984) 309:30-33. Discovery of RGD-binding site on fibronectin.
   Google Scholar
• HAWIGER J, KLOCZEWIAK M, BEDNAREK MA, TIMMONS, S: Platelet receptor recognition domains on the a chain of human fibrinogen: structure function analysis. Bio-chemistry (1989) 28:2909–2914.
   Google Scholar
• RUOSLAHTI E: Integrins. J. Clin. Invest. (1991) 87:1–5.
   Google Scholar
• COX D, AOKI T, SEKI J, MOTOYAMA Y, YOSHIDA K: The •pharmacology of the integrins. Med. Res. Rev. (1994)14:195-228. A detailed review of integrin pharmacology.
   Google Scholar
• HYNES RO: Integrins: versatility, modulation and sig- •naling in cell adhesion. Cell (1992) 69:11-25.Good review on integrin-mediated signalling.
   Google Scholar
• FURMAN MI, GRIGORYEV D, BRAY PF, DISE KR, GOLDSCHMIDT CP: Platelet tyrosine kinase and fibrino-gen receptor activation. Circ. Res. (1994) 75:172–180.
   PubMed Web of Science ®Google Scholar
• SEFTOR RE, SEFTOR EA, GEHLESN KR, STETLER SW, BROWN PD, RUOSLAHTI E, HENDIUX MJ: Role of the alpha v beta 3 integrin in human melanoma cell inva-sion. Proc. Natl. Acad. Sci. USA (1992) 89:1557–1561.
   PubMed Web of Science ®Google Scholar
• NATHAN C, SRIMAL S, FARBER C, SANCHEZ E, KABBASH L, ASCH A, GAILIT J, WRIGHT SD: Cytokine-induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and CD11/CD18 inte-grins. J. Cell Biol. (1989) 109:1341-1349. Shows a role for 132 integrins in neutrophil respiratory burst.
   Google Scholar
• TREZZINI C, SCHUEPP B, MALY FE, JUNGI TW: Evidence that exposure to fibrinogen or to antibodies directed against Mac-1 (CD11b/CD18; CR3) modulates human monocyte effector functions. Br. J. Haematol. (1991) 77:16–24.
   PubMed Web of Science ®Google Scholar
• LIPFERT L, HAIMOVICH B, SCHALLER MD, COBB BS, PAR-SONS JT, BRUGGE JS: Integrin-dependent phosphoryla-tion and activation of the protein tyrosine kinase pp125FAK in platelets. J. Cell Biol. (1992) 119:905–912.
   PubMed Web of Science ®Google Scholar
• FERRELL JJ, MARTIN GS: Tyrosine specific protein phos-phorylation is regulated by glycoprotein II1b-IIIa in platelets. Proc. Natl. Acad. Sci. USA (1989) 86:2234–2238.
   PubMed Web of Science ®Google Scholar
• GOLDEN A, BRUGGE JS, SHATTIL SJ: Role of platelet membrane glycoprotein I1b-111a in agonist-induced ty-rosine phosphorylation of platelet proteins. J. Cell Biol. (1990) 111:3117–3127.
   PubMed Web of Science ®Google Scholar
• HUANG MM, LIPFERT L, CUNNINGHAM M, BRUGGE JS, GINSBERG MH, SHAIilL SJ: Adhesive ligand binding tointegrin alpha Irb beta 3 stimulates tyrosine phospho-rylation of novel protein substrates before phosphory-lation of pp125FAK. J. Cell Biol. (1993) 122:473–483.
   PubMed Web of Science ®Google Scholar
• SHATTIL SJ, HAIMOVICH B, CUNNINGHAM M, LIPFERT L, PARSONS JT, GINSBERG MH, BRUGGE JS: 'Tyrosine phos-phorylation of pp125FAK in platelets requires coordi-nated signaling through integrin and agonist receptors. J. Biol. Chem. (1994) 269:14738-14745. Shows co-stimulatory nature of platelet GPIlb-BIa.
   Google Scholar
• TAKAYAMA H, EZUMI Y, ICHINOHE T OKUMA M: Involve- ment of GPlIb-illa on human platelets in phosphoty- 15. Oa rosine-specific dephosphorylation. Biocbem. Biophys. Res. Commun. (1993) 194:472–477.
   PubMedGoogle Scholar
• LI RY, GAITS F, RAGAB A, RAGAB TJ, CHAP TJ: Transloca-tion of an SH2-containing protein tyrosine phos-phatase (SH-PTP1) to the cytoskeleton of thrombin-activated platelets. FEBS Lett. (1989) 343:89–93.
   Google Scholar
• FRANGIONI JV, ODA A, SMITH M, SALZMAN EW, NEEL BG: Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) In human platelets. EMBO J. (1993) 12:4843–4856.
   PubMed Web of Science ®Google Scholar
• COLLER BS: A new murine monoclonal antibody reports on activation dependent change in the conformation and/or microenvironment of the platelet glycoprotein complex. J. Clin. Invest. (1985) 76:101–108.
   PubMed Web of Science ®Google Scholar
• GOULD RJ, POLOKOFF MA, FRIEDMAN PA, HUANG TF, HOLT JC, COOK JJ, NIEWIAROWSKI S: Disintegrins: a family of integrin inhibitory proteins from viper ven-oms. Proc. Soc. EV. Biol. Med. (1990) 195:168-171. A good paper on disintegrins.
   Google Scholar
• COOK NS, KOTTIRSCH G, ZERWES HG: Platelet glycopro- sotein IMAM antagonists. Drugs of the Future (1994) 19:135-159. Excellent review on GPIIb/lIla antagonists.
   Google Scholar
• CHARO IF, SCARBOROUGH RM, DUMEE CP, WOLF D, PHILIPS DR, SWIFT RL: Circulation (1992) 86(Suppl. I):1034.
   Google Scholar
• FEIGEN LP, NICHOLSON NS, KING LW, CAMPION JG, TJOENG FS, PANZER-KNODLE SG: SC-4992, a mimetic of the peptide arginine-glycine-aspartic add phenylalan-ine that blocks platelet aggregation enhances recombi-nant tissue type activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis. J. Pbarmacol. Exp. Therapeut. (1993) 267(3):1191–1197.
   PubMed Web of Science ®Google Scholar
• COX D, MOTOYAMA Y, SEKI J, AOKI T, DOW M, YOSHIDAK: Pentamidine: a non-peptide GPI1b/fla antagonist -In vitro studies on platelets from humans and other spe-cies. Thromb. Haemostas. (1992) 68(6):731–736.
   PubMed Web of Science ®Google Scholar
• COX D, AOKI T, SEKI J, MOTOYAMA Y: FR144633: a novelplatelet GPIlb/IIIa antagonist. Thromb. Haemostas. (1993) 69:706.
   Web of Science ®Google Scholar
• ALIG L, EDENHOFER A, HADVARY P, HURZELER M, ICNOPP D, MULLER M, STEINER B, TRZECIAK A, WELLER T: Low molecular weight, non-peptide fibrinogen receptor an-tagonist. J. Med. Chem. (1992) 35:4393–4407.
   PubMed Web of Science ®Google Scholar
• GOULD RJ, CHANG C, LYNCH RJ, MANNO PD, ZHANG G, BEDNAR B, FRIEDMAN PA, EGBERTSON M, TURCHI LM, ANDERSON PS, HARTMAN G: Thromb. Haemostas. (1993) 69:976.
   Google Scholar
• FEIGEN L, NICHOLSON N, TArrE B, PANZER-KNODLE S,SALYERS A, HAAS N, SZALONY J, ZABLOCKI J: Thromb. Haemostas. (1993) 69:1071.
   Google Scholar
• MULLER T, SCHURER H, WALDMANN L, BAUER E, HIM-MELSBACH F, BINDER K: Thromb. Haemostas. (1993) 69:975.
   Google Scholar
• PIKE NB, FOSTER MR, HORNBY EJ, LUMLEY P: Thromb.Haemostas. (1993) 69:1071.
   Google Scholar
• GOULD RJ, BARRETT JS, ELLIS JD, HOLAHAN MA, STRA-NIERI MT, THEOHARIDES AD, LYNCH JJ, FRIEDMAN PA, DUGGAN ME, IHLE NC, ANDERSON PS, HARTMAN GD: Thromb. Haemostas. (1993) 69:1.
   Google Scholar
• GOLDSCHMIDT CPJ, SCHULMAN SP, CHANDRA NC, DISE KR, GERSTENBLITH G: Blocking platelets' GPIIb/Ma re-ceptor in unstable angina patients. J. Am. Coll. Cardiol. (1994) Spedal Issue:415A.
   Google Scholar
• KLEIMAN N, OHMAN M, CALIFF R, GEORGE B, KEREIAKES seD, AGLTIRRE F, WEISMAN H, SCHAIBLE T, TOPOL E: Pro-found inhibition of platelet aggregation with mono-clonal antibody 7E3 Fab after thrombolytic therapy. J. Am. Coll. Cardiol. (1993) 22:381-389. Clinical data on anti-GPIIb/HIa antibodies for thrombolysis.
   Google Scholar
• TOPOL EJ, CALIFF RM, WEISMAN HF, ELLIS SG, TCHENG •JE, WORLEY S, IVANHOE R, GEORGE BS, FINTEL D,WESTON M: Randomized trial of coronary intervention with antibody against platelet Erb/Ma integrin for re-duction of clinical restenosis: results at six months. Lancet (1994) 343:881-886. Clinical data on efficacy of anti-GPIIb/IlIa antibodies.
   Google Scholar
• GARCIA JH, LIU KF, YOSHIDA Y, LIAN J, CHEN S, DELZOPPO GJ: Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am. J Patbol. (1994) 144(1):188–199.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, BERNAT A, MAFFRAND JP: Importance of platelets in experimental venous thrombosis in the rat. Blood (1992) 80(9):2281–2286.
   PubMed Web of Science ®Google Scholar
• DIAMANTOPOULOS EJ, RAPTIS SA, MOULOPOULOS SD: Increased platelet activity in diabetic macroangiopathy. Horm. Metabol. Res. Suppl. (1992) 26:95–102.
   PubMedGoogle Scholar
• JONES CR, AMBROS RJ, RAPOLD HJ, STEINER B, WELLER T, VANHEININGEN P, CRIJINS HJ, JONKMAN JH, HADVARY P: Thromb. Haemostas. (1993) 69:560.
   Google Scholar
• PEERLINK K, DELEPELEIRE I, GOLDBERG M, PANEBIANCO D, VERMYLEN J, ARNOUT J: Circulation (1992) 86(Suppl. I): 866.
   Google Scholar
• SIMOONS ML, DEBOER MJ, VAN DENBRAND MJ, VAN- •MILTENBURG AJ, HOORNIJE JC, HEYNDRICKX GR, VANDER WIEKEN LR, DEBONO D, RUTSCH W, SCHAIBLE TF: Randomized trial of a GPITh/Illa platelet receptor blocker in refactory unstable angina. Circulation (1994) 89:596-603. Clinical data on GPIIb/Illa antibodies in unstable angina.
   Google Scholar
• SCHULMAN SP, GOLDSCHMIDT CPJ, NAVETTA Fl, CHAN-DRA NC, GUERCI AD, CALIFF RM: Integrelin in unstable angina: a double-blind randomized trial. Circulation (1993) 88:1608.
   Google Scholar
• ANDERSON HV, REVANA M, ROSALES 0, BRANNIGAN L,STUART Y, WEISMAN H, WILLERSON JT: Intravenous administration of a monoclonal antibody to the platelet GPI1b/IlIa receptor to treat abrupt dosure during coro-nary angioplasty. Am. J. Cardiol. (1992) 69:1373–1376.
   PubMed Web of Science ®Google Scholar
• TCHENG J, KLEIMAN N, HARRINGTON R, MICK M, NAVETTA Fl, WORLEY S: Outcome of patients treated with the GPUb/Hia inhibitor Integrelin during coro-nary angioplasty: results of IMPACT study. Circulation (1993) 88:1595.
   Google Scholar
• TAKADA Y, HEMLER ME: The primary structure of theVLA-2/collagen receptor alpha 2 subunit (platelet GP1a): homology to other integrins and the presence of a possible collagen binding domain. J. Cell Biol. (1989) 109:397–407.
   PubMed Web of Science ®Google Scholar
• COX D, AOKI T, SEKI J, MOTOYAMA Y, YOSHIDA K: Pentamidine is a specific, non-peptide GPI:Ill/Ma an-tagonist. Thromb. Haemostas. (1995). In press. Suggests a possible link between LIBS and the release reaction.
   Google Scholar
• ••
   Google Scholar
• STEINER B, HADVARY P, ROUX S, WELLER T: Thromb. Haemostas. (1991) 65:812.
   Google Scholar
• BROOKS M, CATALFAMO J: Buccal mucosa bleeding timeis prolonged in canine models of primary hemostatic disorders. Thromb. Haemostas. (1993) 70(9:777–780.
   PubMedGoogle Scholar
• PERUTELLI P, MOM PG: Biochemical and molecular basisof Glanzmann's thrombasthenia. Haematologica (1992) 77:421–426.
   PubMed Web of Science ®Google Scholar
• GOLD HK, GIMPLE LW, YASUDA T, LEINBACH RC, WERNER W, HOLT R, JORDAN R, BERGER H, COLLEN D, COLLER BS: Pharmacodynamic study of F(ab')2 frag-ments of marine monoclonal antibody 7E3 directed against human platelet glycoproteinffb/Ma in patients with unstable angina pectoris. J. Clin. Invest. (1990) 86:651–659.
   PubMed Web of Science ®Google Scholar
• DECATERINA R, LANZA M, MANCA G, STRATA GB, MAI IERS, SALVATORE L: Bleeding time and bleeding events: an analysis of the relationship of the bleeding time test with parameters of surgical bleeding. Blood (1994) 84(10):3363–3370.
   PubMed Web of Science ®Google Scholar
• ROUX S, BUNTING S, KOUNS WC, STEINER B: Overdosing of potent GPM/Ma antagonists differentially prolongs the bleeding time in guinea pigs. Thromb. Haemostas. (1993) 69:560.
   Web of Science ®Google Scholar
• COX D, AOKI T, SEKI J, MOTOYAMA Y, YOSHIDA K: Characterization of the binding of FK633 to the platelet fibrinogen receptor. Submitted for publication.
   Google Scholar
• DU XP, PLOW EF, FRELINGER A, O'TOOLE TE, LOFTUS JC, •GINSBERG MH: Ligands 'activate' integrin alpha ffb beta3 (platelet GPM/ilia). Cell (1991) 65(3):409–416. Important paper on induction of LISS by RGDS.
   Google Scholar
• DELANTY N, JENNING L, MORAN N, CATELLA F, FITZGER-ALD GA, FITZGERALD DJ: Antagonism of platelet glyco-protein IMAM receptor in stable angina: effects of platelet activity and receptor conformation. Ciculation (1993) 88(4):1.
   Google Scholar
• COX D, AOKI T, SEKI J: GPM/Ma: LISS and tyrosine phosphorylation. Submitted for publication.
   Google Scholar
• GOODALL AH, WILSON DJ, LUMLEY P: The effect of the fibrinogen receptor antagonist, GR144053, upon fi-brinogen binding and p-selectin expression in human platelets; analysis using flow cytometry. Thromb. Haemostas. (1993) 69(6):1071.
   Web of Science ®Google Scholar
• MAZOYER E, LEVY TS, RENDU F, HERMANT L, LU H, FIAT AM, JOLLES P, CAEN J : KRDS, anew peptide derived from human lactotransferrin, inhibits platelet aggregation and release reaction. Furl. Biochem. (1990) 194(1):43–49.
   Web of Science ®Google Scholar
• CHRISTIE DJ, SAURO SC, CAVANAUGH AL, KAPLAN ME: Severe thrombocytopenia in an acquired immunodefi-ciency syndrome patient associated with pentamidine-dependent antibodies specific for glycoproteinlIb/Ma. Blood (1993) 82(0):3075–3080.
   PubMedGoogle Scholar
• ELICES MJ, HEMLER ME: The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor on others. Proc. NatL Acad. Sci. USA (1989) 86:9906–9910.
   PubMed Web of Science ®Google Scholar
• PLOW EF, MARGUERIE GA, GINSBERG MH: Fibronectinbinding to thrombin-stimulated platelets: Evidence for fibrin(ogen) independent and dependent pathways. Blood (1985) 6601:26-32. KUNICKI TJ: Platelet membrane glycoproteins and their function: an overview. Blut (1989) 59:30-34. THIAGARAJAN P, KELLY KL: Exposure of binding sites for vitronectin on platelets following stimulation. J. Biol. Chem. (1988) 263:3035.
   Google Scholar
• STAATZ WD, FOK KF, ZUTTER MM, ADAMS SP, RO-DRIGUEZ BA, SANTORO SA: Identification of a te1rapep-tide recognition sequence for the alpha 2 beta integrin in collagen. J. Biol. Chem. (1991) 266:7363–7367.
   PubMed Web of Science ®Google Scholar
• STAATZ WD, WALSH JJ, PEXTON T, SANTORO SA: Thealpha 2 beta 1 integrin cell surface collagen receptor binds to the alpha 1 (0-CB3 peptide of collagen. J. Biol. Chem. (1990) 265:4778–4781.
   PubMed Web of Science ®Google Scholar
• VIRMANI R, KOLODGIE FD, FORMAN M, FARB A, JONES R:Reperfusion injury in the ischemic myocardium. Cardiovasc. Pathol. (1992) 1:117–129.
   PubMedGoogle Scholar
• SVENDSEN JH, HONSON PR, ALI S, BAANDRUP U, HAUNSOS: Leukocyte depletion attenuates permeability to small hydrophilic solutes following ischemia and reperfu-sion. Cardiovasc. Res, (1993) 27(7)1288–1294.
   Google Scholar
• MOREL F, DOUSSLERE J, VIGNAIS PV. The superoxide oxidase of phagocytic cells. Physiological, molecular and pathological aspects. Eur. J. Biochem. (1991) 201(3):523–546.
   Google Scholar
• ARNAOUT MA: Structure and function of the leukocyteadhesion molecules CD11/CD18. Blood (1990) 75:1037–1050.
   PubMed Web of Science ®Google Scholar
• KISHIMOTO TK, LARSON RS, CORBI AL, DUSTIN ML, STAUNTON DE, SPRINGER TA: The leukocyte integrins. Adv. Immunol. (1989) 46:149–182.
   PubMed Web of Science ®Google Scholar
• BAN K, IKEDA U, TAKAHASHI M, KANBE T, KASAHARA T,SHIMADA K. Expression of intracellular adhesion mole-cule-1 on rat cardiac myocytes by monocyte chemoat-tractant protein-1. Cardiovasc. Res. (1994) 28(8):1258–1262.
   Google Scholar
• DERIAN CK, SANTULLI RJ, RAO P, SOLOMON HF, BARRETTJA: Inhibition of chemotactic peptide-induced neutro-phil adhesion to vascular endothelium by cAMP modu-lators. J. Immunol. (1995) 154(1):308–317.
   PubMed Web of Science ®Google Scholar
• VIRMANI R, KOLODGIE FD, FORMAN M, FARB A, JONES R:Reperfusion injury in the ischemic myocardium. Cardiovasc. Patbol. (1992) 1:117–129.
   PubMedGoogle Scholar
• GRESHAM HD, GOODWIN JL, ALLEN PM, ANDERSON DC, BROWN EJ: A novel member of the integrin receptor family mediates Arg-Gly-Asp stimulated neutrophil phagocytosis. J. Cell Biol. (1989) 108:1935–1943.
   PubMed Web of Science ®Google Scholar
• ZHOU M, BROWN EJ: Leukocyte response integrin and intewin-associated protein act as a signal transduction unit in generation of a phagocyte respiratory burst J. Exp. Med. (1993) 178:1165–1174.
   PubMed Web of Science ®Google Scholar
• WILSON I, GILLINOU AM, CURTIS WE, DINATALE J, BURCH soRM, GARDNER TJ, CAMERON DE: Inhibition of neutrophil adherence improves postischemic ventricular per-formance of the neonatal heart. Circulation (1993) 88:11737-11739. This paper shows the role of 02 integrins in neutrophil function.
   Google Scholar
• BATOR JM, WEITZBERG M, BURCH RM: Nt9H-(2,7-di-methylfluoreny1-9-methoxy)carbony1J-L-leucine, NPC 15669, prevents neutrophil adherence to endothelium and inhibits CD11b/CD18 up-regulation. Immunophar-macol. (1994) 23(2):139–149.
   Google Scholar